The KU Drug Research Center was founded as a centralized facility and core staff, to help collaborators translate basic science into drug discovery programs and has embraced a two-fold strategy in creating an environment for the drug discovery and development:
KU Drug Research Center will combine computational and experimental methods to elucidate, design, validate and apply new pharmacological concepts and strategies to the development and use of therapeutics and diagnostics. KU Drug Research Center will provide an integrated “systems” approach assisted by high-throughput screening techniques to elucidate drug mechanisms of action during discovery, target identification and in clinical trials. Such an endeavor will incorporate the ongoing research for the design and synthesis of novel, drug-like chemical scaffolds, and biologics to address the therapeutic needs. In addition, computational chemistry and molecular biophysics studies to predict and to define target proteins, druggable sites, potential binding affinities will be among the major activities of the center.
The KU Drug Research Center will accept collaborative projects in any therapeutic area where the collaborator has a significant interest and commitment to the program, while focusing internal efforts on cancer, stem cell research, neuroscience and emerging infectious diseases. There is a major commitment to the use of experimental disease models, as well as human-derived cell/engineered tissue models early in the discovery process.
Contact Details
Burak Erman
Professor
Department of Chemical and Biological Engineering
College of Engineering
Koç University
Rumelifeneri Yolu, 34450 Sariyer, Istanbul Turkey
Phone: +90 (212) 338-1704
Fax : +90 (212) 338-1548
Berman@ku.edu.tr
http://home.ku.edu.tr/~iam/About_Us.html
Murat Barlas, the longest serving board member for the Turkish Pharmaceutical Manufacturers Association, discusses the need for a new perspective in government-industry relations in the Turkish pharmaceutical industry, and the…
The Turkish minister of labour and social security comments on the country’s deep commitment to providing for the health of citizens while maintaining sustainability and continuous improvement of services. How…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Turkey is a key market in the region for Servier, says general manager Philippe Méa, largely due to the country’s relatively strong and stable vision for the healthcare industry. The…
Turkey has been a high priority market for Actelion since the company’s relatively recent beginnings, and the general manager of the local affiliate discusses his affiliate efforts to improve awareness…
Bayer Turkey’s healthcare division head discusses how the company adapted to the post 2009 pharmaceutical pricing environment by shrinking their portfolio and focusing strongly on key growth products, launched recently…
Medipol hospital’s medical director discusses the private institution’s current role in the Turkish healthcare system, and their plans for expansion in the coming years. How did Medipol come into existence,…
Professor Burak Erman, the leader of the Drug Research Center at Koç University, and his colleague Hakan Orer, discuss the early activities of the center as a catalyst for collaboration…
Janssen’s MD in Turkey discusses how true innovation is still recognized in Turkey, and how products that meet unmet medical needs are given early access to the country and reimbursement.…
IMS’s top consultant in Turkey discusses the common pattern that companies in Turkey have and must follow to adapt to today’s market, and the importance of heeding market signals, such…
The managing director of Otsuka’s 50-50 joint venture with Turkish giant Abdi Ibrahim, Abdi Ibrahim Otsuka, discusses the mutual advantage the companies can offer each other, and branding Abdi Ibrahim…
Turkey’s Minister of Health discusses the major achievements of his party in the area of healthcare since 2003, and the key priorities for the country’s healthcare system moving forward. During…
See our Cookie Privacy Policy Here
